Press release
Biosimilars Market Is Thriving According To New Report: Opportunities Rise For Stakeholders By 2026 With Top Companies Sandoz International GmbH, Apotex, Biocon, Zydus Cadila Healthcare, Celltrion, Pfizer, Hexal, Accord Healthcare
Biosimilars are biopharmaceutical drug having active components, which are similar to one that has previously been licensed. They are identical copies of the original products and can be manufactured only when the patent for the original innovator product expires. Biologics or biosimilars are sensitive to changes in manufacturing process due to the higher molecular complexity.Ask For Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/750
Biosimilars are generally derived from living cells of plants, animals, yeast, bacteria and viruses, through genetic engineering processes including controlled gene expression and recombinant DNA technology. In 2010, the Food and Drug Administration (FDA) approved biosimilars as a part of Patient Protection and Affordable Care Act. The approval process is based on thorough demonstration of similarity and comparability with existing approved product.
Patent expiry of drugs and increasing government initiatives for biosimilars to drive growth of the biosimilars market
Increasing demand for cost-effective drugs, increasing number of geriatric population, high healthcare expenditure, increasing government support and initiatives to develop and promote biosimilars, strategic collaborations to enhance productivity and clinical trial for development of biosimilars are major factors driving growth of the market. According to the American Health and Drug Benefits in 2013, an estimated sale of biosimilars was more than US$ 1 billion annually. For instance, global sales of biosimilars was projected to reach US$ 7.19 billion for Remicade (infliximab) and US$ 5.98 billion for Avastin (bevacizumab), owing to high adoption of biosimilar drugs by doctors and patients. Furthermore, expiry and termination of pharmaceuticals drugs such as Humira, Enbrel and Remicade is providing significant opportunity for new players to enter the market.
Competitive Analysis
Key players operating in the biosimilars market include Sandoz International GmbH, Apotex, Biocon, Zydus Cadila Healthcare, Celltrion, Pfizer, Hexal, Accord Healthcare, Harvest Moon Pharmaceuticals, Eli Lilly, and Teva Pharmaceuticals. Leading manufacturers are focusing on outsourcing the production of biosimilar drugs with strategic collaborations to replace existing drugs. For instance, in August 2016, the FDA approved Sandoz for the biosimilar Erelzi for treatment of multiple inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, ankylosing spondylitis and juvenile idiopathic arthritis.
Availability of biosimilar drugs at cost effective rate is expected to boost growth of biosimilars market in Asia Pacific
Regional segmentation of the biosimilars market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The first biosimilar, Sandoz’s Zarxio was approved by FDA in 2015 for sale in North America. According to the American Society of Health-System Pharmacists survey in 2013, around 99% of 214 surveyed pharmacy directors reported shortage of at least one oncologic drug with distribution of biosimilars.
Request Customization @ https://www.coherentmarketinsights.com/insight/request-customization/750
Also, biosimilars market in North America region is expected to gain significant traction, owing to increasing prevalence of cancer, autoimmune diseases, kidney failures, and growth hormone deficiency. Biosimilar drugs provide cost effective treatment options for various diseases such as diabetes, rheumatoid arthritis and cancer, thus providing opportunities for growth of market in China and India. Furthermore, biosimilars market in Asia Pacific region is expected to witness higher growth, availability of cost effective biosimilars, high adoption rate, and consistent guidelines issued by regulatory bodies.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilars Market Is Thriving According To New Report: Opportunities Rise For Stakeholders By 2026 With Top Companies Sandoz International GmbH, Apotex, Biocon, Zydus Cadila Healthcare, Celltrion, Pfizer, Hexal, Accord Healthcare here
News-ID: 1691072 • Views: …
More Releases from Coherent Market Insights - Biotechnology

Wearable Patch Market 2030 Emerging Trends and Global Demand During the COVID-19 …
Coherent Market Insights published a report, titled,"Wearable Patch Market, by Technology (Connected and Regular), by Application (Monitoring, Drug Delivery, and Diagnostics), by End User (Healthcare and Fitness & Sports), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027."
Wearable patches are used for monitoring and diagnosis of chronic diseases. Increasing prevalence of diseases such as atrial…

Recombinant Protein Market To Witness Robust Expansion Throughout The Forecast P …
Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research. Increased understanding of oncogenic signaling pathways and proteins involved in the same has increased the targeting ways, wherein, recombinant proteins such as immune checkpoint, growth factors, and antibodies are used. These proteins are used…

Biosimilar Pipeline Analysis Market Outlook 2019: Rapidly Develop by key Players …
Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness…

Cancer Biomarkers Market Rapid Growth 2019 by leading players BioMerieux S.A., B …
The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies.
Free Request Sample Copy…
More Releases for Biosimilar
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Biosimilar Insulin Market Access
Boston, MA
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer…
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants…
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development
Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin
Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact…
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of…
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.…